SAN JOSE, Calif., Dec. 18 Patent 7,309,486 issued on12/18/07 to NexGen Biomedical, Inc. founder Mark Zamoyski of San Jose,California discloses a better way of using Genentech's drug Herceptin(R)against breast cancer. The patent discloses that today's practice ofconcurrent administration of Herceptin(R) with conventional phase specificchemotherapy results in antagonistic action between the two classes of drugs.In later stage cancers, these protocols only increase median survival byseveral months.
Patent 7,309,486 discloses novel protocols that allow the two classes ofchemotherapeutics to function synergistically. The protocols are designed toprovide a way of holding the cancer in check indefinitely.
All proliferating cells progress through 4 distinct phases termed G1, S,G2, and M. "S-Phase cytotoxics, such as Pfizer's Camptosar(R) or Eli Lilly'sGemzar(R), are capable of killing virtually all cells that are in the S-Phase,however, in the best case, only around one third of cancer cells are typicallyin the S-Phase during chemotherapy," explains Mark Zamoyski, the inventor."The patented protocols boost the number of cells in the S-Phase by exploitingthe cancer's unique mutation profile to establish a "road block" to aggregatea large number of cancer cells at a point prior to the S-Phase, the road blockis then removed to allow the wave of cancer cells to enter the S-Phase duringthe administration time of the S-Phase cytotoxic chemotherapy, and then theroad block is reestablished to start aggregating surviving cancer cells forthe next administration of S-Phase cytotoxic chemotherapy."
The abstract contained in the patent has been incorrectly truncated and acorrect synopsis of the patent is available at http://www.nexgen.biz underCell Cycle Synchronous Chemotherapy.
SOURCE NexGen Biomedical, Inc.